Le Lézard
Classified in: Health, Business
Subject: ACC

DSM - Repurchase of Shares (25 - 31 August 2017)


HEERLEN, Netherlands, September 1, 2017 /PRNewswire/ --

Royal DSM, a global science-based company active in health, nutrition and materials, has repurchased 188,430 of its own shares in the period from 25 August 2017 up to and including 31 August 2017 at an average price of ?64.01. This is in accordance with the repurchase, covering existing option plans and stock dividends, announced on 14 August 2017. The consideration of this repurchase was ?12.1 million.

     (Logo: http://photos.prnewswire.com/prnh/20160803/395298LOGO )

The total number of shares repurchased under this program to date is 474,284 shares for a total consideration of ?30.3 million.

For more detailed information see the 'Daily transaction details 1.6m Share Repurchase Program announced 14 Aug 2017'.

DSM - Bright Science. Brighter Living.tm 

Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in life sciences and materials sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders simultaneously. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM and its associated companies deliver annual net sales of about ?10 billion with approximately 25,000 employees. The company is listed on Euronext Amsterdam. More information can be found at http://www.dsm.com.

Forward-looking statements

This press release may contain forward-looking statements with respect to DSM's future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is leading.

For more information:
DSM Corporate Communications
Stephen Hufton
tel. +31(0)45-5782017        
e-mail [email protected]

DSM Investor Relations
Dave Huizing
tel. +31(0)45-5782864
e-mail [email protected]

 

PDF: http://mma.prnewswire.com/media/551065/DSM_repurchase_of_shares.pdf  

 

    PRN NLD


These press releases may also interest you

at 15:02
Prominently featured in The Inner Circle, Lee C. Ferguson, DO, FACS is acknowledged as a Pinnacle Lifetime Member for his contributions as a Vascular Surgeon. Dr. Ferguson, a distinguished dual board-certified vascular surgeon and endovascular...

at 15:00
The Honourable David J. McGuinty, Member of Parliament for Ottawa South,  on behalf of the Honourable Mark Holland, Minister of Health, will hold a news conference to announce funding to improve palliative care. MP McGuinty will be available to...

at 14:43
Sugar Kayne Radio, an innovative internet radio station founded by Matthew Kayne, also known as DJ Sugar Kayne, is set to launch on 2nd June. Located in the heart of North West London, Sugar Kayne Radio aims to revolutionize the online music...

at 14:38
Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA published the FDA Voices: "A Milestone in Facilitating the Development of Safe and Effective Biosimilars," by Sarah Yim,...

at 14:32
Curve Health, a trailblazer in innovative healthcare solutions, is proud to announce a strategic partnership with MindCare, a leading provider of behavioral health services, with a focus on enhancing care delivery within Skilled Nursing Facilities...

at 14:05
Yoneda Labs, the Y Combinator startup building a foundation model for chemists working in drug discovery, today announced it has raised $4 million in seed capital from Khosla Ventures, 500 Emerging Europe, 468 Capital, Fellows Fund, and Y Combinator....



News published on and distributed by: